In a patient with unresectable, multifocal recurrent cutaneous squamous cell carcinoma and underlying T-cell large granular lymphocytic leukemia with baseline moderate pancytopenia, is anti–PD-1 therapy (e.g., cemiplimab) an appropriate and safe treatment option?